MichaelGibsonMD

Oncology • Nashville, TN

Gastrointestinal Cancer, Head & Neck Cancer

Associate Professor of Medical Oncology, Case Western University Seidman Cancer Center

Join to view full profile

Dr. Gibson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gibson's full profile

Already have an account?

Office
3601 The Vanderbilt Clinic
Nashville, TN 37232
Phone+1 615-322-3000

Fax+1 615-936-0605

Summary

Dr. Michael Gibson is an oncologist in Nashville, TN and is affiliated with multiple hospitals in the area, including University Hospitals Cleveland Medical Center and Vanderbilt University Medical Center. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 20 years. He specializes in gastrointestinal cancer, hiv/aids related, head & neck cancer, and hematologic oncology and is experienced in lung cancer, head and neck oncology, thyroid neoplasms, gastrointestinal oncology, and general medical oncology.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2000 - 2004
Johns Hopkins UniversityResidency, Internal Medicine, 1996 - 1999
Johns Hopkins University School of MedicineClass of 1996

Certifications & Licensure

TN State Medical License 2017 - 2025
AL State Medical License 2020 - 2020
OH State Medical License 2013 - 2019
PA State Medical License 2007 - 2014
MD State Medical License 1999 - 2008
American Board of Internal Medicine Medical Oncology

Clinical Trials

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Start of enrollment: 2008 Jun 01
Completed
Phase 3
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer Start of enrollment: 2008 Oct 01
Completed
Phase 2
Phase II Study of Irinotecan and Panitumumab Start of enrollment: 2009 May 01
Completed
Phase 2
Computed Tomography (CT) Perfusion Imaging of Lung Cancer Start of enrollment: 2009 Jun 01
Terminated
Not Applicable
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies Start of enrollment: 2011 Aug 01
Withdrawn
Phase 2
Phase II Study of RAD001 Head and Neck Cancer Start of enrollment: 2010 Jan 01
Terminated
Phase 2
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer Start of enrollment: 2011 Apr 27
Completed
Phase 2
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2011 Oct 26
Active, not recruiting
Phase 1, Phase 2
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors Start of enrollment: 2020 Aug 31
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.
Eric Michael Lander, Vasily N Aushev, Brandon M Huffman, Diana Hanna, Punashi Dutta
JCO Precision Oncology. 2024-12-01
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma.
Margaret C Wheless, Margaret Comer, Michael K Gibson
Current Oncology Reports. 2024-11-01
3 citations
Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Matthew R Strickland, Eric M Lander, Michael K Gibson, David H Ilson, Jaffer A Ajani
Journal of the National Comprehensive Cancer Network. 2024-03-19

Other

Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus
Gibson MK, Choi NC
http://www.uptodate.com/contents/radiation-therapy-chemoradiotherapy-neoadjuvant-approaches-and-post
UpToDate, Wolters Kluwer Health - 2013-03-28
Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas
Gibson MK, Atasoy A, Berry MF
http://www.uptodate.com/contents/multimodality-approaches-to-potentially-resectable-esophagogastric-
UpToDate, Wolters Kluwer Health - 2013-03-22
Epidemiology, pathobiology, and clinical manifestations of esophageal cancer
Gibson MK, Sampliner RE
http://www.uptodate.com/contents/epidemiology-pathobiology-and-clinical-manifestations-of-esophageal
UpToDate, Wolters Kluwer Health - 2012-12-07
Diagnosis and staging of esophageal cancer
Gibson MK, Saltzman JR
http://www.uptodate.com/contents/diagnosis-and-staging-of-esophageal-cancer
UpToDate, Wolters Kluwer Health - 2012-11-01
Management of locally advanced unresectable esophageal cancer
Gibson MK, Heron DE
http://www.uptodate.com/contents/management-of-locally-advanced-unresectable-esophageal-cancer
UpToDate, Wolters Kluwer Health - 2012-08-15
Join now to see all

Press Mentions

Michael Gibson Votes with FDA Panel to Limit Immunotherapy IndicationOctober 30th, 2024
University Hospitals Seidman Cancer Center Enrolls First Patient in New National Head and Neck Cancer StudyFebruary 23rd, 2017
Dr. Michael Gibson&Carly O'Brien–New Treatment Helps Those Suffering W/ Head & Neck Cancer 12.28.16December 28th, 2016
Join now to see all